ABSTRACT

Background

Previous studies have demonstrated that ursodeoxycholic acid (UDCA) possesses anti-inflammatory, antioxidant, and anti-fibrotic properties, and it may reduce the degree of liver damage caused by nonalcoholic steatohepatitis (NASH). However, the effectiveness of UDCA in improving liver function and histology in cases of NASH remains unclear. Therefore, we performed a meta-analysis to assess the efficacy of UDCA in the treatment of NASH.

Methods

PubMed, Web of Science, Embase, Cochrane, and other databases were searched for randomized controlled trials (RCTs) published before 1 January 2022, in which UDCA was used to treat patients with NASH.

Results

A total of 8 studies with 655 participantsmet the criteria for inclusion in this meta-analysis. The forest plot displayed that UDCA treatment significantly reduced blood concentrations of alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT). However, the pooled effect size results did not suggest any significant effect of UDCA on anthropometric characteristics or hepatic histology.

Conclusion

UDCA therapy can effectively reduce serum levels of ALT and GGT in patients with NASH but has no significant effects on physical characteristics or liver histology. Further large-scale and dose-response clinical studies are needed to evaluate the clinical potential of UDCA in treating NASH.

中文翻译：

---

熊去氧胆酸治疗非酒精性脂肪性肝炎的疗效：系统评价和荟萃分析

摘要

背景

以往的研究表明，熊去氧胆酸（UDCA）具有抗炎、抗氧化和抗纤维化的特性，可降低非酒精性脂肪性肝炎（NASH）引起的肝损伤程度。然而，UDCA 在改善 NASH 病例中的肝功能和组织学方面的有效性仍不清楚。因此，我们进行了一项荟萃分析，以评估 UDCA 在 NASH 治疗中的疗效。

方法

在 PubMed、Web of Science、Embase、Cochrane 和其他数据库中搜索了 2022 年 1 月 1 日之前发表的随机对照试验 (RCT)，其中 UDCA 用于治疗 NASH 患者。

结果

共有 8 项研究共 655 名参与者符合纳入本荟萃分析的标准。森林图显示 UDCA 处理显着降低了丙氨酸氨基转移酶 (ALT) 和 γ-谷氨酰转移酶 (GGT) 的血液浓度。然而，汇总效应量结果并未表明 UDCA 对人体测量特征或肝组织学有任何显着影响。

结论

UDCA 治疗可有效降低 NASH 患者的血清 ALT 和 GGT 水平，但对身体特征或肝脏组织学无明显影响。需要进一步的大规模和剂量反应临床研究来评估 UDCA 在治疗 NASH 中的临床潜力。